Updated Meta-analysis Of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors And Glucagon-Like Peptide-1 Receptor Agonists In Black Patients

Type 2 diabetes mellitus (T2DM) prevalence rates are increasing, while expectations are rather pessimistic.1 Recent, large observational studies have demonstrated that black patients feature increased odds for suffering from T2DM,2 while they experience an increased risk for the development of T2DM related co-morbidities and all-cause mortality, compared to Caucasian patients.3 Black patients experience a higher prevalence of other classic cardiovascular risk factors, which inevitably lead to significant disparities in the incidence of major adverse cardiovascular events (MACEs),4 with T2DM representing a strong and independent risk factor both for cardiovascular morbidity and mortality.

Source: The American Journal of Cardiology - October 9, 2020 Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Stavropoulos, Konstantinos Imprialos, Michael Doumas Source Type: research